EA201591802A1 - Синтез и композиция аминокислотных линкерных групп, конъюгированных с соединениями, применяемыми для направленной визуализации опухолей - Google Patents
Синтез и композиция аминокислотных линкерных групп, конъюгированных с соединениями, применяемыми для направленной визуализации опухолейInfo
- Publication number
- EA201591802A1 EA201591802A1 EA201591802A EA201591802A EA201591802A1 EA 201591802 A1 EA201591802 A1 EA 201591802A1 EA 201591802 A EA201591802 A EA 201591802A EA 201591802 A EA201591802 A EA 201591802A EA 201591802 A1 EA201591802 A1 EA 201591802A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- tumors
- synthesis
- amino
- composition
- compounds
- Prior art date
Links
- 150000001413 amino acids Chemical group 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title abstract 2
- 206010028980 Neoplasm Diseases 0.000 title 1
- 230000015572 biosynthetic process Effects 0.000 title 1
- 238000003786 synthesis reaction Methods 0.000 title 1
- 238000012800 visualization Methods 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 5
- 239000003446 ligand Substances 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 125000001747 pteroyl group Chemical group [H]C1=C([H])C(C(=O)[*])=C([H])C([H])=C1N([H])C([H])([H])C1=C([H])N=C2N([H])C(N([H])[H])=NC(=O)C2=N1 0.000 abstract 1
- 239000000523 sample Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
- A61K49/0052—Small organic molecules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
- A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
- A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
- A61K49/0032—Methine dyes, e.g. cyanine dyes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
- A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
- A61K49/0032—Methine dyes, e.g. cyanine dyes
- A61K49/0034—Indocyanine green, i.e. ICG, cardiogreen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D475/00—Heterocyclic compounds containing pteridine ring systems
- C07D475/02—Heterocyclic compounds containing pteridine ring systems with an oxygen atom directly attached in position 4
- C07D475/04—Heterocyclic compounds containing pteridine ring systems with an oxygen atom directly attached in position 4 with a nitrogen atom directly attached in position 2
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/62—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
- G01N21/63—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
- G01N21/64—Fluorescence; Phosphorescence
- G01N21/6428—Measuring fluorescence of fluorescent products of reactions or of fluorochrome labelled reactive substances, e.g. measuring quenching effects, using measuring "optrodes"
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56966—Animal cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
- G01N33/582—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with fluorescent label
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/62—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
- G01N21/63—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
- G01N21/64—Fluorescence; Phosphorescence
- G01N21/6428—Measuring fluorescence of fluorescent products of reactions or of fluorochrome labelled reactive substances, e.g. measuring quenching effects, using measuring "optrodes"
- G01N2021/6432—Quenching
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/62—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
- G01N21/63—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
- G01N21/64—Fluorescence; Phosphorescence
- G01N21/6428—Measuring fluorescence of fluorescent products of reactions or of fluorochrome labelled reactive substances, e.g. measuring quenching effects, using measuring "optrodes"
- G01N2021/6439—Measuring fluorescence of fluorescent products of reactions or of fluorochrome labelled reactive substances, e.g. measuring quenching effects, using measuring "optrodes" with indicators, stains, dyes, tags, labels, marks
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2201/00—Features of devices classified in G01N21/00
- G01N2201/06—Illumination; Optics
- G01N2201/061—Sources
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/24—Immunology or allergic disorders
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Cell Biology (AREA)
- Physics & Mathematics (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Food Science & Technology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Physiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Zoology (AREA)
- Virology (AREA)
- Hospice & Palliative Care (AREA)
- Optics & Photonics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Настоящее изобретение относится к соединениям, которые пригодны в качестве зондов, флуоресцирующих в ближней инфракрасной области, где соединения включают i) птероиловый лиганд, который связывается с рецепторным белком-мишенью, ii) молекулу красителя и iii) молекулу линкера, которая включает аминокислоту или ее производное. В раскрытии дополнительно описываются способы и композиции для получения и применения соединений, способы, включающие соединения, и наборы, включающие соединения.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361791921P | 2013-03-15 | 2013-03-15 | |
PCT/US2013/056629 WO2014149069A1 (en) | 2013-03-15 | 2013-08-26 | Synthesis and composition of amino acid linking groups conjugated to compounds used for the targeted imaging of tumors |
Publications (2)
Publication Number | Publication Date |
---|---|
EA201591802A1 true EA201591802A1 (ru) | 2016-08-31 |
EA029738B1 EA029738B1 (ru) | 2018-05-31 |
Family
ID=51527878
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA201591802A EA029738B1 (ru) | 2013-03-15 | 2013-08-26 | Синтез и композиция аминокислотных линкерных групп, конъюгированных с соединениями, применяемыми для направленной визуализации опухолей |
Country Status (13)
Country | Link |
---|---|
US (7) | US9333270B2 (ru) |
EP (3) | EP2968335B1 (ru) |
JP (5) | JP6192799B2 (ru) |
CN (3) | CN105228628B (ru) |
AU (4) | AU2013383382B2 (ru) |
BR (1) | BR112015022810B1 (ru) |
CA (3) | CA2903994C (ru) |
EA (1) | EA029738B1 (ru) |
ES (1) | ES2765896T3 (ru) |
HK (1) | HK1218257A1 (ru) |
IL (3) | IL240509B (ru) |
MX (3) | MX358184B (ru) |
WO (3) | WO2014149069A1 (ru) |
Families Citing this family (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BRPI0809442A2 (pt) | 2007-03-27 | 2014-09-09 | Radiomedix Inc | Composições para terapia e formação de imagens direcionada |
DK2721045T3 (en) | 2011-06-20 | 2017-07-24 | Radiomedix Inc | COMPOSITIONS, METHODS OF SYNTHESIS AND USE OF CARBOHYDRATE TARGETED AGENTS |
US20170232119A1 (en) * | 2013-03-15 | 2017-08-17 | Purdue Research Foundation | Synthesis and composition of amino acid linking groups conjugated to compounds used for the targeted imaging of tumors |
JP6192799B2 (ja) * | 2013-03-15 | 2017-09-06 | パーデュー・リサーチ・ファウンデーションPurdue Research Foundation | 腫瘍の標的画像化に使用される化合物にコンジュゲートしているアミノ酸連結基の合成および組成物 |
EP3071971B1 (en) * | 2013-11-19 | 2019-04-24 | Purdue Research Foundation | Patient selection method for inflammation |
US10280307B2 (en) | 2014-11-05 | 2019-05-07 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Class of stable heptamethine cyanine fluorophores and biomedical applications thereof |
EP3294296A4 (en) | 2015-05-12 | 2018-12-26 | Medibeacon Inc. | Compositions and methods for assessing eye vasculature |
FR3036622B1 (fr) * | 2015-05-25 | 2017-05-19 | Fluoptics | Traceur fluorescent ciblant multivalent optimise. |
FR3036621B1 (fr) | 2015-05-25 | 2017-05-19 | Fluoptics | Traceur fluorescent ciblant multivalent dans le proche infrarouge pour imagerie optique. |
US10842887B2 (en) | 2015-09-09 | 2020-11-24 | On Target Laboratories, LLC | PSMA-targeted NIR dyes and their uses |
US9808538B2 (en) * | 2015-09-09 | 2017-11-07 | On Target Laboratories, LLC | PSMA-targeted NIR dyes and their uses |
US11555821B2 (en) | 2016-03-16 | 2023-01-17 | On Target Laboratories, Inc. | CA IX-NIR dyes and their uses |
US10557854B2 (en) * | 2016-03-16 | 2020-02-11 | On Target Laboratories, LLC | CA IX—NIR dyes and their uses |
EP3493855A4 (en) | 2016-08-02 | 2020-04-01 | ISI Life Sciences, Inc. | METHOD FOR DETECTION OF CANCER CELLS. |
EP3496762A1 (en) | 2016-08-11 | 2019-06-19 | The U.S.A. as represented by the Secretary, Department of Health and Human Services | Near-ir light-cleavable conjugates and conjugate precursors |
US10786580B2 (en) * | 2016-09-09 | 2020-09-29 | On Target Laboratories, LLC | Cholecystokinin 2 receptor targeted NIR imaging and use thereof |
EP3510399B1 (en) * | 2016-09-09 | 2023-03-01 | On Target Laboratories, LLC | Psma-targeted nir dyes and their uses |
WO2018081254A1 (en) * | 2016-10-26 | 2018-05-03 | Cao Group, Inc. | Cancer binding chromatic peptides that are targeted for disintegration by radiant energy |
WO2018101473A1 (ja) * | 2016-12-02 | 2018-06-07 | 国立大学法人東京大学 | 化合物、葉酸受容体可視化蛍光プローブ及びそれらの使用 |
EP3555627B1 (en) | 2016-12-14 | 2023-11-22 | Purdue Research Foundation | Fibroblast activation protein (fap)-targeted imaging and therapy |
US10753942B2 (en) | 2017-05-15 | 2020-08-25 | Indicator Systems International, Inc. | Methods to detect remnant cancer cells |
US10539567B2 (en) * | 2017-05-15 | 2020-01-21 | Indicator Systems International, Inc. | Biopsy methods and devices |
JP2021513988A (ja) * | 2018-02-15 | 2021-06-03 | チルドレンズ ナショナル メディカル センターChildren’S National Medical Center | 胆道系及び腎臓系の蛍光マーカーとして使用するためのヘプタメチン系シアニン |
CN108840815A (zh) * | 2018-05-29 | 2018-11-20 | 苏州百源基因技术有限公司 | 一种荧光标记的氨基酸及其制备方法和用途 |
CN108727245B (zh) * | 2018-07-02 | 2021-09-28 | 广州中医药大学(广州中医药研究院) | 一种水杨酸类化合物及其制备方法和应用 |
KR102150415B1 (ko) | 2018-12-07 | 2020-09-01 | 원광대학교 산학협력단 | 암 표적용 화합물 및 이의 용도 |
JP7160694B2 (ja) | 2019-01-08 | 2022-10-25 | 日立Geニュークリア・エナジー株式会社 | 流体接触部材及び流体接触部材の製造方法 |
US11892403B2 (en) | 2019-06-20 | 2024-02-06 | Cilag Gmbh International | Image synchronization without input clock and data transmission clock in a pulsed fluorescence imaging system |
US11716533B2 (en) | 2019-06-20 | 2023-08-01 | Cilag Gmbh International | Image synchronization without input clock and data transmission clock in a pulsed fluorescence imaging system |
US11986160B2 (en) | 2019-06-20 | 2024-05-21 | Cllag GmbH International | Image synchronization without input clock and data transmission clock in a pulsed hyperspectral imaging system |
US11516387B2 (en) | 2019-06-20 | 2022-11-29 | Cilag Gmbh International | Image synchronization without input clock and data transmission clock in a pulsed hyperspectral, fluorescence, and laser mapping imaging system |
US20200397246A1 (en) | 2019-06-20 | 2020-12-24 | Ethicon Llc | Minimizing image sensor input/output in a pulsed hyperspectral, fluorescence, and laser mapping imaging system |
US20210353151A1 (en) * | 2020-05-12 | 2021-11-18 | On Target Laboratories, LLC | Targeted fluorescent markers in combination with a flexible probe |
CN112010862B (zh) * | 2020-10-23 | 2021-03-30 | 南京诺源医疗器械有限公司 | 一种主动靶向叶酸受体近红外荧光分子及其制备方法 |
CN114014843B (zh) * | 2021-11-17 | 2022-09-20 | 北京大学第一医院 | 一种psma靶向核素/荧光双模态配体和分子探针与应用 |
US11986540B2 (en) * | 2022-02-23 | 2024-05-21 | On Target Laboratories, LLC | Compositions including pafolacianine for the identification of malignant lesions |
CN114751907A (zh) * | 2022-03-17 | 2022-07-15 | 南京诺源医疗器械有限公司 | 一种主动靶向叶酸受体近红外荧光分子及其制备方法和用途 |
CN115504984B (zh) * | 2022-09-09 | 2023-07-25 | 南京诺源医疗器械有限公司 | 一种靶向α型叶酸受体的培美近红外荧光分子及其制备方法和应用 |
CN115490672B (zh) * | 2022-09-30 | 2023-11-17 | 南华大学 | 一种兼具光热和光动力效应的光敏剂及其制备方法和应用 |
CN116621823B (zh) * | 2023-07-06 | 2023-10-31 | 南京诺源医疗器械有限公司 | 诊断转移淋巴结近红外荧光示踪剂、合成方法及应用 |
Family Cites Families (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4337339A (en) * | 1979-04-30 | 1982-06-29 | Baker Instruments Corp. | Process for preparation of folic acid derivatives |
US5716596A (en) | 1992-06-23 | 1998-02-10 | Diatide, Inc. | Radioactively labeled somatostatin-derived peptides for imaging and therapeutic uses |
US5871711A (en) | 1992-06-23 | 1999-02-16 | Diatide, Inc. | Radioactively-labeled somatostatin-derived peptides for imaging and therapeutic uses |
DE19717904A1 (de) * | 1997-04-23 | 1998-10-29 | Diagnostikforschung Inst | Säurelabile und enzymatisch spaltbare Farbstoffkonstrukte zur Diagnostik mit Nahinfrarotlicht und zur Therapie |
JP2000095758A (ja) | 1998-09-18 | 2000-04-04 | Schering Ag | 近赤外蛍光造影剤および蛍光造影方法 |
US7547721B1 (en) * | 1998-09-18 | 2009-06-16 | Bayer Schering Pharma Ag | Near infrared fluorescent contrast agent and fluorescence imaging |
BR9917587A (pt) | 1999-12-15 | 2002-08-06 | Schering Ag | Agente de contraste fluorescente próximo ao infravermelho e formação de imagem por fluorescência |
CZ304942B6 (cs) | 2000-03-31 | 2015-02-04 | Purdue Research Foundation | Léčivo pro zvyšování specifické eliminace populace tumorových buněk a farmaceutický prostředek obsahující konjugát fosfát-FITC nebo fosfát-dinitrofenyl |
US7597878B2 (en) | 2000-09-19 | 2009-10-06 | Li-Cor, Inc. | Optical fluorescent imaging |
JP4989013B2 (ja) * | 2000-09-19 | 2012-08-01 | リ−コール インコーポレーティッド | シアニン色素 |
EP1363920B1 (en) | 2001-02-07 | 2006-08-23 | Beth Israel Deaconess Medical Center | Modified psma ligands and uses related thereto |
IL158532A0 (en) * | 2001-05-02 | 2004-05-12 | Purdue Research Foundation | Treatment and diagnosis of macrophage mediated disease |
WO2006101845A2 (en) * | 2005-03-16 | 2006-09-28 | Endocyte, Inc. | Synthesis and purification of pteroic acid and conjugates thereof |
EP1904183B1 (en) * | 2005-07-05 | 2014-10-15 | Purdue Research Foundation | Pharmaceutical composition for the treatment of osteoarthritis |
US7547712B2 (en) * | 2006-02-27 | 2009-06-16 | Nabi Biopharmaceuticals | Methods for decreasing the toxic effects of nicotine on fetuses in pregnant women |
WO2007139815A2 (en) * | 2006-05-23 | 2007-12-06 | Purdue Research Foundation | Imaging and therapeutic method using progenitor cells |
CA2668197A1 (en) | 2006-11-03 | 2008-05-15 | Philip S. Low | Ex vivo flow cytometry method and device |
US8168804B2 (en) * | 2007-06-29 | 2012-05-01 | Vanderbilt University | Large stoke shift NIR dyes |
EP2268317B1 (en) * | 2008-03-14 | 2020-02-26 | VisEn Medical, Inc. | Integrin targeting agents and in vivo and in vitro imaging methods using the same |
WO2010033733A1 (en) | 2008-09-17 | 2010-03-25 | Endocyte, Inc. | Folate receptor binding conjugates of antifolates |
US8916137B2 (en) * | 2008-11-07 | 2014-12-23 | The General Hospital Corporation | Monofunctional carbocyanine dyes for in vivo and in vitro imaging |
CN101440282B (zh) * | 2008-12-18 | 2012-06-27 | 中国药科大学 | 近红外荧光分子探针及其合成方法和用途 |
CA2754492A1 (en) * | 2009-03-05 | 2010-09-10 | Purdue Research Foundation | Method for early imaging of atherosclerosis |
EP2419478B1 (en) * | 2009-04-17 | 2018-02-28 | Li-Cor, Inc. | Fluorescent imaging with substituted cyanine dyes |
US20130071321A1 (en) | 2010-05-28 | 2013-03-21 | Purdue Research Foundation | Delivery of agents to inflamed tissues using folate-targeted liposomes |
US9377466B2 (en) * | 2010-09-06 | 2016-06-28 | Modpro Ab | Compounds and methods |
WO2012054784A1 (en) * | 2010-10-20 | 2012-04-26 | Li-Cor, Inc. | Fluorescent imaging with substituted cyanine dyes |
US10080805B2 (en) * | 2012-02-24 | 2018-09-25 | Purdue Research Foundation | Cholecystokinin B receptor targeting for imaging and therapy |
WO2013130776A1 (en) * | 2012-02-29 | 2013-09-06 | Purdue Research Foundation | Folate receptor alpha binding ligands |
JP6192799B2 (ja) * | 2013-03-15 | 2017-09-06 | パーデュー・リサーチ・ファウンデーションPurdue Research Foundation | 腫瘍の標的画像化に使用される化合物にコンジュゲートしているアミノ酸連結基の合成および組成物 |
-
2013
- 2013-08-26 JP JP2016500088A patent/JP6192799B2/ja active Active
- 2013-08-26 BR BR112015022810-0A patent/BR112015022810B1/pt active IP Right Grant
- 2013-08-26 MX MX2015013223A patent/MX358184B/es active IP Right Grant
- 2013-08-26 AU AU2013383382A patent/AU2013383382B2/en active Active
- 2013-08-26 US US14/010,098 patent/US9333270B2/en active Active
- 2013-08-26 WO PCT/US2013/056629 patent/WO2014149069A1/en active Application Filing
- 2013-08-26 CN CN201380074692.8A patent/CN105228628B/zh active Active
- 2013-08-26 EA EA201591802A patent/EA029738B1/ru not_active IP Right Cessation
- 2013-08-26 CA CA2903994A patent/CA2903994C/en active Active
- 2013-08-26 EP EP13878809.6A patent/EP2968335B1/en active Active
- 2013-10-04 EP EP13878632.2A patent/EP2968614B1/en active Active
- 2013-10-04 CN CN201380074694.7A patent/CN105120903A/zh active Pending
- 2013-10-04 WO PCT/US2013/063593 patent/WO2014149073A1/en active Application Filing
- 2013-10-04 MX MX2015011830A patent/MX2015011830A/es unknown
- 2013-10-04 JP JP2016500094A patent/JP6270981B2/ja active Active
- 2013-10-04 US US14/046,916 patent/US9254341B2/en active Active
- 2013-10-04 AU AU2013383386A patent/AU2013383386A1/en not_active Abandoned
- 2013-10-04 CA CA2903727A patent/CA2903727C/en active Active
- 2013-12-19 US US14/135,099 patent/US9233175B2/en active Active
- 2013-12-19 MX MX2015013219A patent/MX2015013219A/es unknown
- 2013-12-19 JP JP2016500131A patent/JP2016512240A/ja active Pending
- 2013-12-19 ES ES13877792T patent/ES2765896T3/es active Active
- 2013-12-19 EP EP13877792.5A patent/EP2972320B1/en active Active
- 2013-12-19 AU AU2013381391A patent/AU2013381391A1/en not_active Abandoned
- 2013-12-19 WO PCT/US2013/076659 patent/WO2014143309A1/en active Application Filing
- 2013-12-19 CA CA2902205A patent/CA2902205A1/en not_active Abandoned
- 2013-12-19 CN CN201380074662.7A patent/CN105492905B/zh active Active
-
2014
- 2014-03-12 US US14/207,130 patent/US9061057B2/en active Active
-
2015
- 2015-05-19 US US14/715,799 patent/US9341629B2/en active Active
- 2015-08-12 IL IL240509A patent/IL240509B/en active IP Right Grant
- 2015-08-18 IL IL240673A patent/IL240673B/en active IP Right Grant
- 2015-08-25 IL IL240828A patent/IL240828A/en active IP Right Grant
- 2015-11-30 US US14/953,928 patent/US9782497B2/en active Active
-
2016
- 2016-06-02 HK HK16106296.0A patent/HK1218257A1/zh unknown
- 2016-09-08 US US15/259,719 patent/US9789208B2/en active Active
-
2017
- 2017-05-18 AU AU2017203340A patent/AU2017203340B2/en active Active
- 2017-05-31 JP JP2017107741A patent/JP2017149776A/ja active Pending
- 2017-09-05 JP JP2017170413A patent/JP2017214425A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA201591802A1 (ru) | Синтез и композиция аминокислотных линкерных групп, конъюгированных с соединениями, применяемыми для направленной визуализации опухолей | |
BR112019000970A2 (pt) | proteínas de ligação ao antígeno multiespecíficas e métodos de uso das mesmas | |
CY1119219T1 (el) | Anti-ceacam5 αντισωματα και χρησεις αυτων | |
CY1120471T1 (el) | Αντισωματα κατα του cd70 | |
EA201490677A1 (ru) | Связывающие антиген cd27l белки | |
MX2018008680A (es) | Moleculas de union especifica a proteina de union a adn de respuesta transactiva de 43 kda (tdp-43). | |
EA201390472A1 (ru) | Новые молекулы, связывающиеся с egfr, и их иммуноконъюгаты | |
BR112018074453A2 (pt) | proteínas de ligação biespecíficas ligando uma protéina imunomoduladora e um antígeno tumoral | |
PH12017502390A1 (en) | Constructs targeting ny-eso-1 peptide/mhc complexes and uses thereof | |
EA201391509A1 (ru) | Твердофазные формы кабазитаксела и способы их получения | |
CY1121466T1 (el) | Αντισωματα εναντι προσδεματων υποδοχεα β1 βραδυκινινης | |
MA40074A (fr) | Composés liant ras multivalents | |
MX2017012352A (es) | Construccion dirigida a complejos de peptido de alfa-fetoproteina/complejo principal de histocompatibilidad (afp/cph) y usos de los mismos. | |
EA201791733A1 (ru) | Производные 9h-пирролодипиридина | |
BR112018005573A2 (pt) | ?polipeptídeos de ligação a cd3? | |
CO6351750A2 (es) | Composiciones y métodos para anticuerpos que se dirigen a la proteina de complementos c5 | |
UA117575C2 (uk) | Антитіло, яке специфічно зв'язується з il-17a та його застосування | |
EA201591091A1 (ru) | Антигенсвязывающие белки для bcma | |
PE20160993A1 (es) | Nuevos anticuerpos anti-dpep3 y metodos de uso | |
BRPI0607323B8 (pt) | composições, usos de polipeptídeos e de anticorpos, bem como kits para a detecção de anticorpo que se liga especificamente a um polipeptídeo | |
BR112017006598A2 (pt) | anticorpo de repetições antidipeptídeo derivado de ser humano (dprs) | |
UY33274A (es) | Proteínas de unión a basigina | |
EA201991912A1 (ru) | Составы, содержащие pd-1-связывающие белки, и способы их получения | |
MX2009012358A (es) | Agentes de formacion de imagenes opticas. | |
BR112016014913A8 (pt) | anticorpo, ou um fragmento de ligação ao antígeno do mesmo, conjugado, ácido nucléico, vetor, célula hospedeira, composição farmacêutica, método de preparo de uma cadeia leve de um anticorpo ou fragmento de ligação ao antígeno e método de preparo de um conjugado |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): AM AZ BY KZ KG TJ TM |